Cargando…

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riste, Michael, Marshall, Julia L., Satti, Iman, Harris, Stephanie A., Wilkie, Morven, Lopez Ramon, Raquel, Wright, Danny, Wittenberg, Rachel E., Vermaak, Samantha, Powell Doherty, Rebecca, Lawrie, Alison, Conlon, Christopher P., Cosgrove, Catherine, Gleeson, Fergus, Lipman, Marc, Moss, Paul, Perrin, Felicity, Dedicoat, Martin, Bettinson, Henry, McShane, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073411/ https://www.ncbi.nlm.nih.gov/pubmed/33923628 http://dx.doi.org/10.3390/vaccines9040396

Ejemplares similares

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2019)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
por: Wilkie, Morven, et al.
Publicado: (2020)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

TB vaccine development: where are we and why is it so difficult?
por: Wilkie, Morven E M, et al.
Publicado: (2015)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

Evaluation of Xpert(®) MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial
por: Bunyasi, Erick Wekesa, et al.
Publicado: (2015)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, Angela M, et al.
Publicado: (2011)

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
por: Zhang, Yiling, et al.
Publicado: (2018)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
por: Wajja, Anne, et al.
Publicado: (2018)

Contribution of Xpert(®) MTB/RIF to pediatric TB diagnosis in Mozambique
por: Mutemba, C. M., et al.
Publicado: (2023)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: McShane, Helen, et al.
Publicado: (2016)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
por: Rimal, Raksha, et al.
Publicado: (2022)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil
por: Pereira, Giovana Rodrigues, et al.
Publicado: (2018)

Enhancing TB Case Detection: Experience in Offering Upfront Xpert MTB/RIF Testing to Pediatric Presumptive TB and DR TB Cases for Early Rapid Diagnosis of Drug Sensitive and Drug Resistant TB
por: Raizada, Neeraj, et al.
Publicado: (2014)

Towards new TB vaccines
por: Brazier, Benedict, et al.
Publicado: (2020)

Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model
por: Harrington-Kandt, Rachel, et al.
Publicado: (2018)

Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes
por: Togun, Toyin, et al.
Publicado: (2020)

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge
por: Stylianou, Elena, et al.
Publicado: (2023)

Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India
por: Sachdeva, Kuldeep Singh, et al.
Publicado: (2015)

Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population
por: Raizada, Neeraj, et al.
Publicado: (2015)

Comparison of the Predicted Population Coverage of Tuberculosis Vaccine Candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a Bioinformatics Approach
por: Davila, Jose, et al.
Publicado: (2012)

Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia
por: Ershova, Julia V., et al.
Publicado: (2020)

Correction: Comparison of the Predicted Population Coverage of Tuberculosis Vaccine Candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a Bioinformatics Approach
por: Davila, Jose, et al.
Publicado: (2012)

Diagnosis of paediatric TB using Xpert(®) MTB/RIF Ultra on fresh respiratory samples
por: Sabi, I., et al.
Publicado: (2022)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2008)

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
por: Minhinnick, Alice, et al.
Publicado: (2016)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Catching the Missing Million: Experiences in Enhancing TB & DR-TB Detection by Providing Upfront Xpert MTB/RIF Testing for People Living with HIV in India
por: Raizada, Neeraj, et al.
Publicado: (2015)

Detection of Mycobacterium tuberculosis in clinical sputum by a unique gene in MTB strains called Conserved protein TB18.5 (TB18.5)
por: Luo, Juanxiu, et al.
Publicado: (2021)

The effect of sputum quality and volume on the yield of bacteriologically-confirmed TB by Xpert MTB/RIF and smear
por: Zimba, Onani, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t9tfr5j5o9v67at4c7jn9dcml8